FDA approves Roche's Columvi, the first and only bispecific antibody with a fixed-duration treatment for people with relapsed or refractory diffuse large B-cell lymphoma itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
Glofitamab targets CD3, a protein found on the surface of immune T cells in patients with relapsed or refractory diffuse large B-cell lymphoma, and CD20, a healthy or malignant protein that lines the surfaces of B cells.
Columvi is the first bispecific antibody that can be administered to patients with relapsed or refractory diffuse large B-cell lymphoma for a defined period of time.
Glofitamab is the first bispecific antibody with a fixed-duration treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).